NPHLA Daily — November 5, 2026

Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.

Top development today

What changed today in AI & Technology: 2 new studies

NPHLA tracked 2 new official records on this desk today: 2 new studies. First: New research in Journal of evaluation in clinical practice: “Evaluating Fiscal Credibility Through the Lens of Durability: Value Decay in AI-Enabled Clinical Documentation”.

Metabolic signal

What changed today in Metabolic: 2 trial updates

NPHLA tracked 2 new official records on this desk today: 2 trial updates. First: New trial registered: A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes…

Aesthetics & Longevity signal

What changed today in Aesthetics & Longevity: 1 trial update

NPHLA tracked 1 new official record on this desk today: 1 trial update. First: New trial registered: Autologous Hair Follicle-Derived Secretome and Platelet-Rich Plasma for Premature Ovarian Insufficiency

AI & Technology signal

What changed today in AI & Technology: 1 final rule

NPHLA tracked 1 new official record on this desk today: 1 final rule. First: Final rule published: Medical Devices; Hematology and Pathology Devices; Classification of the Digital Cervical Cytology Slide Imaging System With Artificial Intelligence Algorithm.

One thing worth watching

Comments close: Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information…

November 26, 2026 — verified from the Federal Register comments_close_on.

5 things to know

Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.